• The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035, claims Roots Analysis

    Roots Analysis has done a detailed study on “Regulatory T-Cell Therapies Market, 2021 – 2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

    Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications.

    To order this 145+ page report, which features 90+ figures and 60+ tables, please visit
    https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html

    Key Market Insights

     More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications
     The pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routes
     In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwide
     In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4
     Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effort
     Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets
     The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders
     The future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regions
     In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration

    One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities associated with Treg cell therapies, over the coming decade. The report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market/request-sample.html

    Table of Contents

    1. Preface

    2. Executive Summary

    3. Introduction

    4. Current Market Landscape

    5. Therapy Profiles

    6. Clinical Trial Analysis

    7. Partnerships and Collaborations

    8. Funding and Investment Analysis

    9. Porter’s Five Analysis

    10. Company Profiles

    11. Market Sizing and Opportunity Analysis

    12. Conclusion

    13. Executive Insights

    14. Appendices


    For more information, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html
    You may also be interested in the following reports :
    1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
    2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030
    3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030
    4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030



    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035, claims Roots Analysis Roots Analysis has done a detailed study on “Regulatory T-Cell Therapies Market, 2021 – 2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. To order this 145+ page report, which features 90+ figures and 60+ tables, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html Key Market Insights  More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications  The pipeline features a variety of marketed / clinical stage therapies, targeting a number of different types of immune checkpoints and being investigated for administration via different routes  In the last few years, over 600 clinical studies of various types of immune checkpoint modulation-based therapies, involving nearly 90,000 patients across different centers / hospitals, have been initiated worldwide  In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, developers are actively exploring the therapeutic potential of novel immune checkpoints, beyond PD-L1, PD-1 and CTLA-4  Over time, big pharma players have initiated product development programs focused on immune checkpoint modulation for treating various oncological indications, investing significant capital, time and effort  Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets  The growing interest in this field is also reflected by the 120+ partnerships have been signed in the last two years, involving both international and indigenous stakeholders  The future market, based on the revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across different disease areas, mechanisms and key geographical regions  In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities associated with Treg cell therapies, over the coming decade. The report also includes likely sales forecasts of Treg cell therapies that are in the mid to late stages of development. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market/request-sample.html Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Current Market Landscape 5. Therapy Profiles 6. Clinical Trial Analysis 7. Partnerships and Collaborations 8. Funding and Investment Analysis 9. Porter’s Five Analysis 10. Company Profiles 11. Market Sizing and Opportunity Analysis 12. Conclusion 13. Executive Insights 14. Appendices For more information, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html You may also be interested in the following reports : 1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030 2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030 3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030 4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Regulatory T-Cell Therapies Market | Market Size | Industry Analysis | 2035
    Regulatory T-Cell Therapies Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The cell therapy manufacturing market is estimated to be worth USD 14.5 billion in 2030, predicts Roots Analysis

    In order to meet the demand for cell therapy products and the growing need for effective therapeutic interventions, developers are actively outsourcing certain manufacturing operations, in addition to expanding their in-house capabilities

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (4th Edition), 2021-2030.”

    The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Amongst other elements, the report includes:
     A detailed review of the overall landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cell manufactured, source of cell, scale of operation, purpose of production, manufacturing capabilities / services offered, as well as location of headquarters and their respective manufacturing facilities.
     An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities.
     An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established during the period 2016-2021.
     A review of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain.
     Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients).
     An estimate of the overall, installed capacity for the manufacturing of cell-based therapies.
     An in-depth analysis of cell therapy manufacturers using three versatile representations.
     A detailed analysis of various factors that are likely to influence the price of cell-based therapies.
     An elaborate discussion on the role of automation technologies in improving the current manufacturing methods.
     A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
     A discussion on cell therapy manufacturing regulations across various geographies.
     Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies.
     A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under an elaborate SWOT framework.
     Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Type of Cell Therapy
     T cell therapies
     Dendritic and tumor cell therapies
     NK cell therapies
     Stem cell therapies
     Other ATMPs
     Source of Cell
     Autologous
     Allogeneic
     Scale of Operation
     Clinical
     Commercial
     Purpose of Manufacturing
     In-house Manufacturing
     Contract Manufacturing
     Geographical Regions
     North America
     Europe
     Asia Pacific
     Rest of the World

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/285/request-sample.html

    Key companies covered in the report
     BioNTech Innovative Manufacturing Services
     Cell and Gene Therapy Catapult
     Cell Therapies
     Center for Cell and Gene Therapy, Baylor College of Medicine
     Center for Cell Manufacturing Ireland, National University of Ireland
     Clinical Cell and Vaccine Production Facility, University of Pennsylvania
     Cognate BioServices
     FUJIFILM Cellular Dynamics
     Guy's and St. Thomas GMP Facility, Guy's Hospital
     KBI Biopharma
     Laboratory for Cell and Gene Medicine, Stanford University
     Lonza
     MEDINET
     Minaris Regenerative Medicine
     Molecular and Cellular Therapeutics, University of Minnesota
     Newcastle Cellular Therapies Facility, Newcastle University
     Nikon CeLL innovation
     Rayne Cell Therapy Suite, King's College London
     Roslin Cell Therapies
     Scottish National Blood Transfusion Service, Scottish Centre of Regenerative Medicine
     Sydney Cell and Gene Therapy
     Waisman Biomanufacturing
     WuXi AppTec

    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

    Other Recent Offerings
    1. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
    2. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
    3. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
    4. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
    5. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The cell therapy manufacturing market is estimated to be worth USD 14.5 billion in 2030, predicts Roots Analysis In order to meet the demand for cell therapy products and the growing need for effective therapeutic interventions, developers are actively outsourcing certain manufacturing operations, in addition to expanding their in-house capabilities Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (4th Edition), 2021-2030.” The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Amongst other elements, the report includes:  A detailed review of the overall landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cell manufactured, source of cell, scale of operation, purpose of production, manufacturing capabilities / services offered, as well as location of headquarters and their respective manufacturing facilities.  An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities.  An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established during the period 2016-2021.  A review of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain.  Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients).  An estimate of the overall, installed capacity for the manufacturing of cell-based therapies.  An in-depth analysis of cell therapy manufacturers using three versatile representations.  A detailed analysis of various factors that are likely to influence the price of cell-based therapies.  An elaborate discussion on the role of automation technologies in improving the current manufacturing methods.  A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.  A discussion on cell therapy manufacturing regulations across various geographies.  Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies.  A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under an elaborate SWOT framework.  Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Cell Therapy  T cell therapies  Dendritic and tumor cell therapies  NK cell therapies  Stem cell therapies  Other ATMPs  Source of Cell  Autologous  Allogeneic  Scale of Operation  Clinical  Commercial  Purpose of Manufacturing  In-house Manufacturing  Contract Manufacturing  Geographical Regions  North America  Europe  Asia Pacific  Rest of the World To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/285/request-sample.html Key companies covered in the report  BioNTech Innovative Manufacturing Services  Cell and Gene Therapy Catapult  Cell Therapies  Center for Cell and Gene Therapy, Baylor College of Medicine  Center for Cell Manufacturing Ireland, National University of Ireland  Clinical Cell and Vaccine Production Facility, University of Pennsylvania  Cognate BioServices  FUJIFILM Cellular Dynamics  Guy's and St. Thomas GMP Facility, Guy's Hospital  KBI Biopharma  Laboratory for Cell and Gene Medicine, Stanford University  Lonza  MEDINET  Minaris Regenerative Medicine  Molecular and Cellular Therapeutics, University of Minnesota  Newcastle Cellular Therapies Facility, Newcastle University  Nikon CeLL innovation  Rayne Cell Therapy Suite, King's College London  Roslin Cell Therapies  Scottish National Blood Transfusion Service, Scottish Centre of Regenerative Medicine  Sydney Cell and Gene Therapy  Waisman Biomanufacturing  WuXi AppTec For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html Other Recent Offerings 1. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030 2. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030 3. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030 4. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030 5. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Cell Therapy Manufacturing Market (4th Edition) | Market Size | Industry Analysis | 2030
    Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots Analysis
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • AT PRESENT, MORE THAN 100 COMPANIES ACROSS THE GLOBE CLAIM TO HAVE THE REQUIRED CAPABILITIES TO OFFER TELERADIOLOGY SERVICES FOR INTERPRETATION OF DIFFERENT TYPES OF MEDICAL IMAGES
    During our research, we came across 105 service providers that are presently engaged in providing teleradiology services. The domain is currently dominated by small (40%) and mid-sized players (33%).
    This can be attributed to the fact that healthcare domain has seen a shift from traditional image interpretation services to teleradiology services in the recent years, especially with increase in cases where the patients are not able to frequently visit their healthcare professional due to the lockdowns imposed because of COVID-19 pandemic. Further, increased preference of radiologists to work from home, due to COVID-19, has spurred the establishment of many start-ups in this domain.

    To request for Sample report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-sample.html




    Even though teleradiology services are being provided by players based all across the globe, most of the service providers engaged in this domain (~40%) are headquartered in North America, followed by Asia, Europe, Middle East and North Africa, and South America.

    During our research, we observed that majority (81%) of the teleradiology service providers offer teleradiology services for both CT scan and MRI image interpretations. This is followed by players offering X-ray (67%), ultrasound (60%), and PET (41%). Examples of the companies processing all types of images include (in alphabetical order with no selection criteria) 4ways Healthcare, XXX, XXX, XXX, and Cloudex Radiology.
    To request for customize report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-customization.html

    Currently, majority (18%) of the service providers are offering teleradiology solutions for interpretation of mammography specific images, followed by musculoskeletal (17%), neuroradiology (16%), nuclear medicine (15.5%), cardiology (14%), pediatrics (12.5%), and oncoradiology (25). Some of the players that offer teleradiology solutions for interpretation of all types of subspecialty images include (in alphabetical order, with no selection criteria), XXX, All-American Teleradiology, XXX, XXX, and Narayana Health.



    Majority (84%) of the teleradiology service providers are offering services to hospitals, followed by diagnostic / imaging centers (45%), and patients (11%). Some of the players that offer teleradiology services to all types of end users include (in alphabetical order) include, BalticRAD, XXX, and National Diagnostic Imaging.

    For more information please click on the following link: - https://www.rootsanalysis.com/reports/teraradiology-services-market.html

    Other Recent Offerings
    1. TIL-based Therapies Market, 2021-2030
    2. TCR-based Therapies Market, 2021-2030
    3. Peptide Therapeutics Market, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    AT PRESENT, MORE THAN 100 COMPANIES ACROSS THE GLOBE CLAIM TO HAVE THE REQUIRED CAPABILITIES TO OFFER TELERADIOLOGY SERVICES FOR INTERPRETATION OF DIFFERENT TYPES OF MEDICAL IMAGES During our research, we came across 105 service providers that are presently engaged in providing teleradiology services. The domain is currently dominated by small (40%) and mid-sized players (33%). This can be attributed to the fact that healthcare domain has seen a shift from traditional image interpretation services to teleradiology services in the recent years, especially with increase in cases where the patients are not able to frequently visit their healthcare professional due to the lockdowns imposed because of COVID-19 pandemic. Further, increased preference of radiologists to work from home, due to COVID-19, has spurred the establishment of many start-ups in this domain. To request for Sample report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-sample.html Even though teleradiology services are being provided by players based all across the globe, most of the service providers engaged in this domain (~40%) are headquartered in North America, followed by Asia, Europe, Middle East and North Africa, and South America. During our research, we observed that majority (81%) of the teleradiology service providers offer teleradiology services for both CT scan and MRI image interpretations. This is followed by players offering X-ray (67%), ultrasound (60%), and PET (41%). Examples of the companies processing all types of images include (in alphabetical order with no selection criteria) 4ways Healthcare, XXX, XXX, XXX, and Cloudex Radiology. To request for customize report - https://www.rootsanalysis.com/reports/teraradiology-services-market/request-customization.html Currently, majority (18%) of the service providers are offering teleradiology solutions for interpretation of mammography specific images, followed by musculoskeletal (17%), neuroradiology (16%), nuclear medicine (15.5%), cardiology (14%), pediatrics (12.5%), and oncoradiology (25). Some of the players that offer teleradiology solutions for interpretation of all types of subspecialty images include (in alphabetical order, with no selection criteria), XXX, All-American Teleradiology, XXX, XXX, and Narayana Health. Majority (84%) of the teleradiology service providers are offering services to hospitals, followed by diagnostic / imaging centers (45%), and patients (11%). Some of the players that offer teleradiology services to all types of end users include (in alphabetical order) include, BalticRAD, XXX, and National Diagnostic Imaging. For more information please click on the following link: - https://www.rootsanalysis.com/reports/teraradiology-services-market.html Other Recent Offerings 1. TIL-based Therapies Market, 2021-2030 2. TCR-based Therapies Market, 2021-2030 3. Peptide Therapeutics Market, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Request Sample - Teleradiology Services Market | Remote Diagnosis | Online Health | Telemedicine | Medical Imaging | Market Size | 2030
    Driven by rising demand for remote patient diagnosis, the teleradiology services market is anticipated to grow at an annualized rate of about 17%, till 2030...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • In Order to Cope up with the Current and Future Market Demand, Industry Stakeholders and Researchers are Actively Collaborating to Expanding their Existing Infrastructure and Capabilities
    In the pharmaceutical industry, stakeholders are known to adopt a variety partnership models. Such initiatives not only allow the companies to expand their respective product / therapy, but also to gain additional capabilities in emerging technologies
    In the domain of TIL-based therapies, eleven different types of partnership deals were found to be inked between different stakeholders. These include, acquisition, clinical trial agreement, joint venture, manufacturing agreement, product development agreement, product development and commercialization agreement, product licensing agreement, product supply management agreement, R&D agreement, technology licensing and others.

    During our research, we came across several partnership agreements, inked during the period 2005-2020 (till October). The number of partnerships has increased at a CAGR of 53%, between 2014 and 2020. It is important to highlight that maximum number of partnerships were recorded in 2017, 2018 and 2019, followed by 2015 (6). Majority of the deals signed in 2016, were R&D agreements, followed by agreements signed for technology licensing, clinical trial agreements and manufacturing agreements.

    Majority (33%) of the agreements were signed for R&D (13) and technology and product licensing (8) of TIL-based products. This is followed by agreements focused on manufacturing (15%), clinical trials and product supply management, which account for 5% each of the total partnerships inked in this domain, respectively. Recent examples include the product licensing agreement signed between Iovance Biotherapeutics and TrakCel in September 2017.
    To request for Sample report - https://www.rootsanalysis.com/reports/til-therapies-market/request-sample.html
    Funding Initiatives

    The technological advancements in this domain, and the promising results of preclinical / clinical studies of various product candidates have garnered the attention of several investors. Given the innate advantages offered by immunotherapeutics, this emerging market has done exceedingly well in terms of raising funds. The strong and steady performance, in terms of research-related advances and flow of finances, has been favorable to this market. Investments from venture capital investors have helped start-ups, such as Iovance Biotherapeutics and Cellular Biomedicine Group, to become the current leaders in the TIL-based therapies market.


    To request for customize report - https://www.rootsanalysis.com/reports/til-therapies-market/request-customization.html

    Given the current trend, it can be stated that investment from venture funding rounds is a key enabler for growth in the TIL-based therapies market. Companies in this domain have raised significant capital through venture rounds (30%), amounting to USD 68 billion. Some big-ticket investments include (in decreasing order of amount) Iovance Biotherapeutics (USD 170 million) and Cellular Biomedicine Group (USD 10 million). This is followed by secondary offerings, which account for 24% of the total number of instances, amounting to USD 1.1 billion. Further, we came across 4 instances of venture capital investments received by companies from various industrial and non-industrial organizations. Examples of the players that have received venture capital investments include (in decreasing order of amount) Achilles Therapeutics, Instil Bio, PACT Pharma, Intrexon, KSQ Therapeutics and Phio Pharmaceuticals.
    For additional details, please visit - https://www.rootsanalysis.com/reports/til-therapies-market.html

    You may also be interested in the following titles:
    4. TIL-based Therapies Market, 2021-2030
    5. TCR-based Therapies Market, 2021-2030
    6. Peptide Therapeutics Market, 2021-2030


    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    In Order to Cope up with the Current and Future Market Demand, Industry Stakeholders and Researchers are Actively Collaborating to Expanding their Existing Infrastructure and Capabilities In the pharmaceutical industry, stakeholders are known to adopt a variety partnership models. Such initiatives not only allow the companies to expand their respective product / therapy, but also to gain additional capabilities in emerging technologies In the domain of TIL-based therapies, eleven different types of partnership deals were found to be inked between different stakeholders. These include, acquisition, clinical trial agreement, joint venture, manufacturing agreement, product development agreement, product development and commercialization agreement, product licensing agreement, product supply management agreement, R&D agreement, technology licensing and others. During our research, we came across several partnership agreements, inked during the period 2005-2020 (till October). The number of partnerships has increased at a CAGR of 53%, between 2014 and 2020. It is important to highlight that maximum number of partnerships were recorded in 2017, 2018 and 2019, followed by 2015 (6). Majority of the deals signed in 2016, were R&D agreements, followed by agreements signed for technology licensing, clinical trial agreements and manufacturing agreements. Majority (33%) of the agreements were signed for R&D (13) and technology and product licensing (8) of TIL-based products. This is followed by agreements focused on manufacturing (15%), clinical trials and product supply management, which account for 5% each of the total partnerships inked in this domain, respectively. Recent examples include the product licensing agreement signed between Iovance Biotherapeutics and TrakCel in September 2017. To request for Sample report - https://www.rootsanalysis.com/reports/til-therapies-market/request-sample.html Funding Initiatives The technological advancements in this domain, and the promising results of preclinical / clinical studies of various product candidates have garnered the attention of several investors. Given the innate advantages offered by immunotherapeutics, this emerging market has done exceedingly well in terms of raising funds. The strong and steady performance, in terms of research-related advances and flow of finances, has been favorable to this market. Investments from venture capital investors have helped start-ups, such as Iovance Biotherapeutics and Cellular Biomedicine Group, to become the current leaders in the TIL-based therapies market. To request for customize report - https://www.rootsanalysis.com/reports/til-therapies-market/request-customization.html Given the current trend, it can be stated that investment from venture funding rounds is a key enabler for growth in the TIL-based therapies market. Companies in this domain have raised significant capital through venture rounds (30%), amounting to USD 68 billion. Some big-ticket investments include (in decreasing order of amount) Iovance Biotherapeutics (USD 170 million) and Cellular Biomedicine Group (USD 10 million). This is followed by secondary offerings, which account for 24% of the total number of instances, amounting to USD 1.1 billion. Further, we came across 4 instances of venture capital investments received by companies from various industrial and non-industrial organizations. Examples of the players that have received venture capital investments include (in decreasing order of amount) Achilles Therapeutics, Instil Bio, PACT Pharma, Intrexon, KSQ Therapeutics and Phio Pharmaceuticals. For additional details, please visit - https://www.rootsanalysis.com/reports/til-therapies-market.html You may also be interested in the following titles: 4. TIL-based Therapies Market, 2021-2030 5. TCR-based Therapies Market, 2021-2030 6. Peptide Therapeutics Market, 2021-2030 Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Request Sample - TIL-based Therapies Market 2021-2030 | Industry Analysis | Market Size | 2030
    TIL-based Therapies Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored